Zacks Investment Research on MSN
Here's why you should add Cardinal Health stock to your portfolio now
Cardinal Health CAH is well positioned for continued growth, thanks to the expansion of its speciality portfolio. The firm ...
Zacks Investment Research on MSN
Are GLP-1 drugs becoming a meaningful revenue driver for CAH stock?
Cardinal Health CAH is clearly benefiting from the rapid adoption of GLP-1 therapies, though the impact remains more pronounced on revenues than profitability. In the second quarter of fiscal 2026, ...
CAH's Pharmaceutical and Specialty Solutions segment surged in fiscal Q2'26 with 19% revenue growth to $61B, fueled by specialty drugs, GLP-1 demand and generics momentum.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results